Syngeneic murine tumor models of varying responsiveness to anti-PD-1 antibody (PD-1 mAb) therapy were employed to evaluate the efficacy and tolerability of intratumoral (IT) treatment with mPH-762: BrafV600E/Pten-/- “BP” melanoma, (PD-1 mAb-responsive melanoma) (Cooper et al., 2014), Hepa1-6 (PD-1 mAb-responsive hepatocellular carcinoma); B16-OVA (PD-1 mAb moderately responsive melanoma); and CT26 (PD-1 mAb modestly responsive colon carcinoma) were utilized. The gene discussed is PTEN; the disease is neoplasm.